14.15

0.35% -0.05

After Hours: 14.01 -0.14 -0.99%

Assembly Biosciences Inc (ASMB)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Assembly Biosciences Inc stock is traded at $14.15, with a volume of 18,549. It is down -0.35% in the last 24 hours and up +22.94% over the past month. Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

Previous Close:

$14.20

Open:

$14.2

24h Volume:

18,549

Relative Volume:

0.79

Market Cap:

$108.11M

Revenue:

Net Income/Loss:

$-61.23M

P/E Ratio:

-1.0466

EPS:

-13.5194

Net Cash Flow:

$22.49M

1W Performance:

+4.66%

1M Performance:

+22.94%

6M Performance:

-16.96%

1Y Performance:

-4.78%

1-Day Range:

$14.00

$14.68

1-Week Range:

$13.70

$14.68

52-Week Range:

$7.75

$19.93

Assembly Biosciences Inc Stock (ASMB) Company Profile

Name

Assembly Biosciences Inc

Sector

Healthcare (1170)

Industry

Biotechnology (667)

Phone

(833) 409-4583

Address

TWO TOWER PLACE, SOUTH SAN FRANCISCO

Employee

Twitter

Next Earnings Date

2024-12-06

Latest SEC Filings

ASMB's Discussions on Twitter

Compare ASMB with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ASMB Assembly Biosciences Inc	14.15	103.26M	0	-61.23M	22.49M	-13.52
ONC Beone Medicines Ltd Adr	245.58	26.10B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	442.05	111.96B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.35	42.96M	0	0	0	0.00
VRNA Verona Pharma Plc Adr	81.20	6.39B	0	-153.72M	-103.81M	-2.00
REGN Regeneron Pharmaceuticals Inc	490.28	63.52B	14.09B	4.50B	2.96B	39.28

Assembly Biosciences Inc Stock (ASMB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-25-25	Initiated	Guggenheim	Buy
Sep-20-24	Upgrade	Jefferies	Hold → Buy
Sep-13-21	Initiated	H.C. Wainwright	Neutral
Sep-02-21	Downgrade	William Blair	Outperform → Mkt Perform
Mar-23-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Nov-06-20	Downgrade	Jefferies	Buy → Hold
Oct-19-20	Initiated	Truist	Buy
Oct-16-19	Initiated	Mizuho	Buy
Nov-19-18	Initiated	Leerink Partners	Outperform
Oct-08-18	Upgrade	B. Riley FBR	Neutral → Buy
Aug-08-18	Initiated	Robert W. Baird	Outperform
Apr-13-18	Downgrade	Chardan Capital Markets	Buy → Neutral
Jan-05-18	Initiated	B. Riley FBR, Inc.	Neutral
Nov-08-17	Initiated	Jefferies	Buy
May-30-17	Initiated	Chardan Capital Markets	Buy

View All

Assembly Biosciences Inc Stock (ASMB) Latest News

08:35 AM

When Will Assembly Biosciences, Inc. (NASDAQ:ASMB) Breakeven? - Yahoo

08:35 AM

03:28 AM

Assembly Biosciences, Inc. (NASDAQ:ASMB) Short Interest Up 99.2% in May - Defense World

03:28 AM

May 27, 2025

Assembly Biosciences to Present During the Jefferies 2025 Global Healthcare Conference | ASMB Stock News - GuruFocus

May 27, 2025

Assembly Biosciences to Present During the Jefferies 2025 Global Healthcare Conference - The Manila Times

May 27, 2025

Assembly Bio Leadership Team Set for Key Presentation at Major Jefferies Healthcare Conference - Stock Titan

May 27, 2025

Syndeio Biosciences Launches to Lead the Emerging Field of Synapse-Targeted Neurotherapeutics - Business Wire

May 27, 2025

May 21, 2025

Assembly’s NeosAI, Powered by Microsoft Azure AI Foundry, Sets New Benchmark for Legal Productivity—Backed by Real-World Results - GlobeNewswire Inc.

May 21, 2025

Mizuho Cuts Price Target on Assembly Biosciences to $29 From $36, Keeps Outperform Rating - marketscreener.com

May 21, 2025

May 15, 2025

ABI-4334 outperforms vebicorvir in HBV suppression - BioWorld MedTech

May 15, 2025

May 14, 2025

Assembly Biosciences (ASMB) Reports Q1 Loss, Tops Revenue Estimates - MSN

May 14, 2025

Growth Investors: Industry Analysts Just Upgraded Their Assembly Biosciences, Inc. (NASDAQ:ASMB) Revenue Forecasts By 33% - simplywall.st

May 14, 2025

May 10, 2025

Assembly Biosciences First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance

May 10, 2025

May 09, 2025

Assembly Biosciences: Q1 Earnings Snapshot - New Haven Register

May 09, 2025

Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates - The Manila Times

May 09, 2025

Assembly Biosciences Reports Q1 2025 Earnings - TipRanks

May 09, 2025

May 08, 2025